Happy New Year – 2016

It’s been an interesting year. When I started this site I really didn’t know what was going to happen… in most respects, it has exceeded my expectations. A Few Opening Remarks On a positive note, I genuinely felt support for the mission of trying to create a fresh dialogue around the quality and transparency of ASX-listed companies operating in this…

No more Alchemistry….

I had a fairly sleepless night last night. It wasn’t just that my 3 year-old woke up at 2am with a night terror, or the periodic squawk across the corridor from the newborn. It wasn’t the ill-advised double-expresso I had after dinner, or even the premonition of a 4am wake-up for a day of business…

ACL : Live and Let Die?

I love a good Bond film and my favorite is, without hesitation, “Live and Let Die”. Charismatic villains, gorgeous but complex “starlets”, and Roger Moore at his gorgonzola-best. McCartney’s awesome sound track is surprisingly glam rock for the era, reminding us that after all the optimism and hope of youth – “live and let live” – is…

Alchemia has a VAST problem

It was only two years ago that Alchemia (ASX : ACL) informed us, with great fanfare and celebration, of the collaboration with AstraZeneca involving the VAST program. It was a pretty exciting story, especially for an early-stage platform technology. R&D cost offsets, potential milestones/royalties. Big potential, heady stuff. Two years on, we have seen the company’s fortunes…

ACL : Erratum (Mr. Ken Poutakidis)

By way of follow-up to my previous post on Alchemia (ASX : ACL), I have been informed that my implied statement that Mr Ken Poutakidis, who recently joined the struggling board of ACL, was previously a director of Phosphagenics (ASX : POH) is in fact incorrect. I made a determination on the basis of reasonable information that was…

The Pink Panther Strikes Again

The only true certainty in life is that history will repeat itself, just like that throaty little Shirley Bassey number. In case you haven’t noticed by now I really love what I do – mainly because when history repeats itself, especially the stupid kind, I am there and ready for sarcastic commentary. Like the deranged curator…

NRT, ANP, PYC, ACL, OBJ : A Week in Contrast

Last week was a pretty exciting week in Australian life sciences. Quite a bit happened, in fact I struggled to stay on top of it while being on vacation. We’ve seen a couple of good things happen, like PharmAxis, Sirtex recovery, etc. that are real bright spots on the Aussie biotech landscape. We’ve seen some…